Enzon gets Orphan Drug status for new version of Oncaspar
New Jersey, USA-based Enzon Pharmaceuticals has received European Orphan Drug designation for its Oncaspar-IV (EZN-2285), a next-generation PEG- enhanced version of L-asparaginase. The firm says the product, which is a new version of its Oncaspar, utilizes an efficient modern process for the manufacture of L-asparaginase and an improved PEG linker to enhance stability. The original Oncaspar is used in combination with other chemotherapeutics to treat acute lymphoblastic leukemia. The firm says Oncaspar-IV is designed to enhance the pharmaceutical properties of the original US approved drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze